Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44M Sell
330,000
-75,000
-19% -$8.49M 1.99% 14
2026
Q1
$45.1M Sell
405,000
-100,000
-20% -$11.8M 2.33% 13
2025
Q4
$68.1M Buy
505,000
+145,000
+40% +$15.8M 3.88% 4
2025
Q3
$30.6M Buy
360,000
+260,000
+260% +$15.9M 2.66% 10
2025
Q2
$765K Sell
100,000
-100,000
-50% -$652K 0.1% 74
2025
Q1
$1.25M Buy
+200,000
New +$1.35M 0.12% 79

Other funds holding ABVX

Affinity Asset Advisors's ABVX Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Abivax (ABVX) stake by 19% in Q2 2026, selling an estimated $8.49M and leaving 330,000 shares worth $44M. The position accounts for 1.99% of the portfolio, ranked #14.

Affinity Asset Advisors first reported a position in ABVX in Q1 2025 and has held it in 6 quarters since. The position peaked at $68.1M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Affinity Asset Advisors held 330,000 shares of Abivax worth $44M as of Q2 2026.
  • Affinity Asset Advisors sold 75,000 Abivax shares in Q2 2026, an estimated $8.49M.
  • Abivax made up 1.99% of Affinity Asset Advisors's portfolio in Q2 2026, its #14 holding.
  • Affinity Asset Advisors first reported a position in Abivax in Q1 2025 and has held it in 6 quarters since.
  • Affinity Asset Advisors's Abivax position peaked at $68.1M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.